Literature DB >> 8498558

Adenosine regulates coronary blood flow during increased work and decreased supply.

S E Martin1, S D Lenhard, L S Schmarkey, S Offenbacher, B M Odle.   

Abstract

Adenosine may mediate coronary vasodilation during work-related hyperemia and during ischemia. We tested whether adenosine blockade with 8-p-sulfophenyltheophylline (PSPT) prevented dobutamine-induced hyperemia or magnified the reductions in flow due to vasopressin. Control (n = 8) and test (n = 7) dogs received paired infusions of dobutamine (70 micrograms/min iv for 5 min). Test dogs received PSPT (10 mg/kg iv) between doses. In both groups, paired infusions elicited comparable increases in oxygen consumption. However, in test dogs, the hyperemia was reduced significantly. Thus adenosine mediates the hyperemia of dobutamine. Separately, control dogs (n = 9) received vasopressin (0.6 microgram ic over 5 min); test dogs (n = 7) received PSPT before vasopressin. Vasopressin maximally increased coronary resistance by 3 min; effects were gone by 10 min. With PSPT, coronary resistance was increased further and remained high beyond 10 min. Thus adenosine-mediated vasodilation moderates the severity and duration of ischemia. These results indicate the importance of adenosine in mediating coronary flow during increased demand and reduced supply.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498558     DOI: 10.1152/ajpheart.1993.264.5.H1438

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

1.  The role of adenosine in functional hyperaemia in the coronary circulation of anaesthetized dogs.

Authors:  F Karim; I P Goonewardene
Journal:  J Physiol       Date:  1996-02-01       Impact factor: 5.182

2.  Pannexin 1 is required for full activation of insulin-stimulated glucose uptake in adipocytes.

Authors:  Samantha E Adamson; Akshaya K Meher; Yu-Hsin Chiu; Joanna K Sandilos; Nathaniel P Oberholtzer; Natalie N Walker; Stefan R Hargett; Scott A Seaman; Shayn M Peirce-Cottler; Brant E Isakson; Coleen A McNamara; Susanna R Keller; Thurl E Harris; Douglas A Bayliss; Norbert Leitinger
Journal:  Mol Metab       Date:  2015-07-03       Impact factor: 7.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.